LDS/Medical Tests/15q Deletion, Type I and Type II Characterization, Prader-Willi/Angelman Syndromes, FISH

15q Deletion, Type I and Type II Characterization, Prader-Willi/Angelman Syndromes, FISH

Maternal or paternal deletion of 15q11-q13 causes two distinct syndromes of Prader-Willi (PWS) and Angelman (AS) syndromes, respectively. Maternal uniparental disomy (UPD) in PWS, paternal UPD in AS, or abnormal gene expression and methylation are other mechanisms of inheritance.

The 15q is rich in low-copy repeats and therefore vulnerable to genomic instability. This region also contains six genomic breakpoint (BP) regions, allocated as BP1 to BP6, from the centromeric to telomeric region. Two large types, type I and type II, deletions are phenotypically important. The larger type I deletion spans BP1 and BP3 regions. The smaller type II deletion has a size around 500kb that spans the length of the BP2 and BP3 regions. The type I deletion shows more severe phenotypes than type II. Therefore, the distinction between type I and II deletions is useful in managing the patients.

Phenotypic changes and behavioral differences between type I and type II deletions have been reported in both PWS and AS patients. Type I patients have more severe phenotypic changes then type II, including delayed development and autistic features. Therefore, diagnostic differences between type I and type II deletions it is also important in counseling PWS or AS patients.

Type I and II deletions may be detected by evaluating the RP11-289D12 region on chromosome 15 with specific DNA probes. Type I or type II deletions are reported when deletions of both 289D12 and SNRPN, or 289D12 but not SNRPN, are observed on the same chromosome 15 homolog, respectively. For this deletion detection, 10 metaphase cells from peripheral blood cultures are examined and a 15qter probe signal is used as a control. This test should be ordered in patients diagnosed to carry a deletion of the Prader-Willi/Angelman syndrome critical region.

Differential diagnosis of Prader-Willi and Angelman syndromes with type I and type II deletions in patients with a known deletion of 15q11.1-11.3
  • Two signals with a normal pattern in each metaphase considered negative for the deletion in the region tested
  • Deletion of the critical region by loss of FISH signal pattern considered positive for the deletion in the region tested
  • Detection of larger (BP1-BP3) or smaller (BP2-BP3) deletions by the FISH sequence specific probe will indicate what deletion is present or patient carries

The result is within normal limits. No deletion of the 15q11-q13 critical regions was observed

Fluorescence In Situ Hybridization (FISH) Using DNA Probes.

Amniotic fluid (25 mL), chorionic villi (25 mg), skin biopsy, product of biopsy or stillbirth, blood (5mL in sodium heparin). Tissue samples should be supplied in Hank’s solution.

Stability

Blood: 

  • Ambient: 1-3 days
  • Refrigerated: 3-5 days 

Amniotic fluid and chorionic villi should be transoport and store refrigerated. 

Tissue samples are stable at room temperature for transport and storage. 

NGS, target sequencing.
7 Days
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login